FERTAID
|
|
      
|
DISCPLINES: Embryology Andrology Ultrasound Endocrinology
Modules
 
Information on QA Scheme: AntiSperm Antibodies Review
Comment = The survey was prepared on behalf of Dr David Kay, University of Newcastle, Australia. This scheme is now available for participation.
Number of enrollments =1 [* This indicates only the number of enrollments. Not all participants will have completed the scheme]
List of QA Issues (or Instalments)
Code Title Available from
Su2002A.01 Laboratory Type 1/4/2002
Su2002A.02 Methodology - Fluid 1/4/2002
Su2002A.03 Reasons for testing 1/4/2002
Su2002A.04 Test performed 1/4/2002
Su2002A.05 Methodology 1/1/2002
Su2002A.06 Postive Results. 1/4/2002
Su2002A.07 Clinical Result 1/4/2002
Su2002A.08 Outcome & Comments 1/4/2002
List of Questions asked for QA Scheme:AntiSperm Antibodies Review
ID Question Question Format
156 Do you include a negative control with each run? Defined Options
155 Do you include a positive control with each run? Defined Options
101 Do you participate in an external quality assurance program? Defined Options
106 Do you test cervical mucus ? Defined Options
105 Do you test female serum ? Defined Options
103 Do you test fresh sperm ? Defined Options
104 Do you test male serum ? Defined Options
110 Do you test perform postsurgery testing on reanastomosed males? Defined Options
109 Do you test perform presurgery testing on reanastomosed males? Defined Options
111 Do you test referrals for Assisted Reproduction for antisperm antibodies Defined Options
108 Do you test referrals for tertiary assessments if not tested previously. Defined Options
102 Does your laboratory test for antisperm antibodies? Defined Options
100 How many staff are routinely involved in assessment of antisperm antibodies. Defined Options
151 How many tests did you perform last calendar year? Numeric Outcome
112 How many years experience in testing for antispem antibodies has your senior scentist? Defined Options
146 If a sample from a female patient was clincally significant, what recommendation would you make in your report? Defined Options
145 If a sample from a male patient was clincally significant, what recommendation would you make in your report? Defined Options
152 If you perform the IBT or MAR tests on fresh semen, how many times did you wash the sperm before testing? Defined Options
154 If you perform the Indirect Test, what serum dilution do you use for the initial test. [Indicate dilution level] Numeric Outcome
153 If you use the IBT, how many immunobeads must be attached per spermatozoa to represent a positive outcome. Defined Options
133 The criteria for determining a clinically significant result using the GAT is: Defined Options
131 The criteria for determining a clinically significant result using the IBT is: Defined Options
132 The criteria for determining a clinically significant result using the MAR is: Defined Options
134 The criteria for determining a clinically significant result using the SIT is: Defined Options
135 The criteria for determining a clinically significant result using the TAT is: Defined Options
127 The criteria for determining a positive result using the GAT is: Defined Options
125 The criteria for determining a positive result using the IBT is: Defined Options
126 The criteria for determining a positive result using the MAR is: Defined Options
129 The criteria for determining a positive result using the SIT is: Defined Options
130 The criteria for determining a positive result using the TAT is: Defined Options
120 The GAT (gelatin agglutination test) on female serum Defined Options
119 The GAT (gelatin agglutination test) on male serum Defined Options
115 The IBT (Immunobead test) on female serum. Defined Options
114 The IBT (Immunobead test) on male serum. Defined Options
113 The IBT (Immunobead test) on semen. Defined Options
118 The MAR test on female serum. Defined Options
117 The MAR test on male serum Defined Options
116 The MAR test on semen Defined Options
122 The SIT (sperm immobilisation test) on female serum Defined Options
121 The SIT (sperm immobilisation test) on male serum Defined Options
124 The TAT (tray agglutination test) on female serum Defined Options
123 The TAT (tray agglutination test) on male serum Defined Options
99 What type of laboratory are you? Defined Options
142 What was the incidence of a clinically significant result for male patients in the previous year? Defined Options
144 What was the incidence of a clinically significant result in the previous year for non-vasectomy patients Defined Options
150 What was the incidence of a clinically significant result of female patients in the previous year? Defined Options
149 What was the incidence of a positive result of female patients in the previous year? Defined Options
141 What was the incidence of a postive result for male patients in the previous year? Defined Options
143 What was the incidence of a postive result in the previous year for non-vasectomy patients Defined Options
147 Would you be happy to be contacted by Dr David Kay (bidjk@alinga.newcastle.edu.au) about pregnancy rates and treatment options? Defined Options
Detailed Information on Question: Would you be happy to be contacted by Dr David Kay (bidjk@alinga.newcastle.edu.au) about pregnancy rates and treatment options?
Status This is not a key question for the Scheme    
Type Defined Options
Order Question Options
1 Yes
2 No
 
© FertAid Pty Ltd. 2002 - all pages. All rights reserved.